Results 171 to 180 of about 274,220 (302)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

A realist inspired barriers and facilitators evaluation of the co-creation process in the Youth-centred Participatory Action Project. [PDF]

Health Promot Int
Souza MFS, Chinapaw M, Silva CS, Demetriadou L, Madsen L, Maluleke V, Ndwandwe L, Okafor A, Ogunleye A, Vargas J, Longworth G, Altenburg T, Klaufus L, Omotoso D, Oyeyemi A, Ware L, Palmeira A, Silva MN.   +17 more
europepmc   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Why Women Don't Return: Nurse Perspectives on Follow-Up Care After Abnormal Cervical Cancer Screening Results in Mississippi's Public Health System. [PDF]

Public Health Nurs
Ferrell CD, Hall KC, Reaves S, Wentzensen N, Clarke MA, Stewart MW, Parker A, Wells J, Rives R, Daniels J, Farrington K, Risley C.   +11 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Getting to best practice: a practice-oriented checklist for monitoring clinic-level fidelity to hypertension interventions in a large safety-net healthcare system. [PDF]

BMC Health Serv Res
Korn AR, Gandhi P, R Dopp A, Barron J, Casillas-Salazar R, Durant C, G Morales M, Norwood-Scott E, L Carson S, Casillas A, B Hamilton A, S Mittman B, Park N, Polzin R, Sadia A, Sandesara U, Takada S, Wali S, R Weldon A, F Brown A.   +19 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Disability and dignity: a qualitative systematic review of WASH-related barriers, facilitators and interventions for adults with musculoskeletal disabilities. [PDF]

Front Public Health
Sahu S, Jnyanajyoti M, Kshatri JS, Palo SK, Pati S.   +4 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Advancing dementia-friendly hospital care: a systematic review of healthcare professionals' reported barriers and facilitators using the theoretical domains framework. [PDF]

Age Ageing
Shimelash M, Fu J, Plantinga A, Geelen SJG, Hofman C, Claassen JAHR, van Munster BC.   +6 more
europepmc   +1 more source